CME
Text module with experts’ insights on key studies presented at key global conferences on gynecologic cancers including topics of incorporating immunotherapies into the standard of care in gynecologic cancers, novel targeted agents, and combinations in development, and updated long-term data and confirmatory trial results.
Physicians: Maximum of 1.50 AMA PRA Category 1 Credits™
Released: December 13, 2023
Expiration: December 12, 2024
Share
Nicoletta Colombo, MD, PhD
Associate Professor of Obsterics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Linda R. Duska, MD, MPH
Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia
Keiichi Fujiwara, MD, PhD
Professor of Gynecologic Oncology
Saiama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan
Alexandra Leary, MD, PhD
Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France
Domenica Lorusso, MD, PhD
Associate Professor
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy
David Scott Miller, MD, FACOG, FACS
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas
Kathleen N Moore, MD, MS
Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
ASCO BOD
Oklahoma City, Oklahoma
Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Prof Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France
Brian Slomovitz, MD, MS, FACOG
Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor
Obsterics and Gynecology
Florida International University
Member, Board of Directors
GOG Foundation
Uterine Cancer Lead
GOG Partners
Miami, Florida
Provided by Clinical Care Options, LLC
Supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.
AstraZeneca
Genmab
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novocure
Seagen
This educational program is intended for medical oncologists, gynecologic oncologists, and other healthcare professionals who treat patients with gynecologic cancer.
The goal of this activity is to improve the knowledge, confidence, and competence of learners in selecting individualized treatment regimens for patients with gynecologic malignancies.
Upon completion of this activity, participants should be able to:
Apply new data in cervical, endometrial, and ovarian cancers to clinical practice to expand treatment options and improve outcomes for patients with gynecologic malignancies
Plan individualized treatment strategies, incorporating novel therapies and combination strategies as appropriate, for patients with cervical, endometrial, and ovarian cancers
Assess predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility
Provide education and support throughout all stages of diagnosis and treatment to populations of patients with gynecologic cancers who are at increased risk for poor prognosis
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Nicoletta Colombo, MD, PhD
Associate Professor of Obsterics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Nicoletta Colombo, MD: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Immunogen Merck Sharp & Doheme, Mersana, Nuvation, Oncxerna, Pfizer, Pieris, Roche.
Linda R. Duska, MD, MPH
Professor, Gynecologic Oncology
Vice Chair for Research
Department of Obstetrics and Gynecology
Associate Dean for Clinical Research
University of Virginia School of Medicine
Charlottesville, Virginia
Linda R. Duska, MD, MPH, FACOG, FACS, FASCO: researcher (paid to institution): Aduro Biotech Inc, ARCH Oncology, CE3 Inc, Clinipace Inc, Corcept Therapeutics, Eisia, GlaxoSmithKline, Harpoon Therapeutics, K-Group Beta, Leap Therapeutics, Lycera, Ludwig Institute for Cancer Research, Merck Sharp and Dohme, NRG, OncoQuest, Pfizer, PharmaMar, Plexxikon, Psi Pharma Support America, Seattle Genetics, Syndax; data safety monitoring committee: Agenus, Inovio.
Keiichi Fujiwara, MD, PhD
Professor of Gynecologic Oncology
Saiama Medical University International Medical Center
Hidaka, Japan
Professor of OBGYN
International University of Health and Welfare
Narita, Japan
Keiichi Fujiwara, MD, PhD: consultant/advisor/speaker: Genmab, Sanofi, Seagen, Takeda.
Alexandra Leary, MD, PhD
Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France
Alexandra Leary, MD, PhD: consultant/advisor/speaker: Ability Pharma, Apmonia, AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Owkin; researcher: Ability Pharma, Apmonia, AstraZeneca, Genmab, GlaxoSmithKline, Incyte, Merck Sharp & Dohme, Oseimmuno, Owkin, Pfizer.
Domenica Lorusso, MD, PhD
Associate Professor
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy
Domenica Lorusso, MD, PhD: consultant/advisor/speaker: AstraZeneca, Clovis, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp and Dohme.
David Scott Miller, MD, FACOG, FACS
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Direct and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics and Gynecology
University of Texas Southwestern Medical Center
Dallas, Texas
David Scott Miller, MD, FACOG, FACS: consultant/advisor/speaker: AbbVie, Agenus, AstraZeneca, Asymmetric, Boston Biomedical Research Institute, Eisai, Eisai Europe Limited, EMD Serono, GlaxoSmithKline, Immunogen, Incyte, iTeos Belgium SA, Karyopharm, Merck Sharp & Dohme, Myriad, Novartis, Novocure, Seagen, Tarveda Therapeutics; researcher (paid to institution): Advaxis, Advenchen, Aeterna Zentaris, Agenus, Akesobio, Aprea AB, AstraZeneca, Immunogen, Incyte, Janssen, Karyopharm, Mateon, Merck Sharp & Dohme, Millenium, NVision, Novartis, Pfizer, Regeneron, Syros, Tesaro, Tracon, US Biotest, Xenetic; researcher: EMD Serono Research & Development, Leap.
Kathleen N Moore, MD, MS
Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
ASCO BOD
Oklahoma City, Oklahoma
Kathleen Moore, MD, MS: consultant/advisor/speaker: Aadi, AstraZeneca, Aravive, Alkermes, Blueprint Pharma, Caris, Clovis, Eisai, Genentech, GlaxoSmithKline, Immunogen, Inxmed, Imab, Janssen, Lilly, Merck, Mereo, Mersana, Myriad, Novartis, Onconova, Oncxerna, Pannavance, Regeneron, VBL Therapeutics, Verastem, Zentalis; independent contractor: GOG Partners Associate Director.
Ana Oaknin, MD, PhD
Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Ana Oaknin, MD, PhD: consultant/advisor/speaker: Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelisis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, ImmunoGen, Itheos, Merck Sharp & Dohme de España, Mersana Therapeutics, NovoCure, OneXerna Therapeutics, PharmaMar, Regeneron, SA Pharma, Sattucklabs, Seagen and Sutro Biopharma.
Prof Isabelle Ray-Coquard, MD, PhD
President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France
Isabelle Ray-Coquard, MD, PhD: consultant/advisor/speaker: Adaptimmune, Agenus, Amgen, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Deciphera, Eisai, Exelixis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, ImmunoGen, Merck Sharp & Dohme, Mersana Therapeutics, NovoCure, OncXerna Therapeutics, PharmaMar, Regeneron, SA Pharma, Seagen, Sutro Biopharma.
Brian Slomovitz, MD, MS, FACOG
Director
Gynecologic Oncology
Mount Sinai Medical Center
Professor
Obsterics and Gynecology
Florida International University
Member, Board of Directors
GOG Foundation
Uterine Cancer Lead
GOG Partners
Miami, Florida
Brian Slomovitz, MD, MS FACOG: consultant/advisor/speaker: AstraZeneca, Clovis, Eisai, Genmab, Gilead, GlaxoSmithKline, Merck, Novartis, Novocure, Regeneron, Seagen.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 13, 2023, through December 12, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.